MUM1 expression in cutaneous CD30+ lymphoproliferative disorders: A valuable tool for the distinction between lymphomatoid papulosis and primary cutaneous anaplastic large-cell lymphoma

British Journal of Dermatology

Volumn 158, Issue 6, 2008, Pages 1280-1287

  Kempf, W ^a,b   Kutzner, H ^c   Cozzio, A ^b   Sander, C A ^d   Pfaltz, M C ^e   Muller B ^a   Pfaltz, M ^a  

^a Kempf und Pfaltz   (Switzerland)

^b UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^c Dermatopathologische Gemeinschaftspraxis   (Germany)

^d Asklepios Hospital   (Germany)

^e UNIVERSITY OF BASEL   (Switzerland)

Author keywords

Anaplastic large cell lymphoma; CD30; Cutaneous lymphoma; Lymphomatoid papulosis; MUM1

Indexed keywords

CD30 ANTIGEN; FORMALDEHYDE; INTERFERON REGULATORY FACTOR 4; MONOCLONAL ANTIBODY; PARAFFIN;

ANAPLASTIC CARCINOMA; ARTICLE; CONTROLLED STUDY; DIFFERENTIAL DIAGNOSIS; HODGKIN DISEASE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LARGE CELL LYMPHOMA; LYMPHOMATOID PAPULOSIS; LYMPHOPROLIFERATIVE DISEASE; PRIORITY JOURNAL; PROTEIN EXPRESSION; T CELL LYMPHOMA; TUMOR CELL;

ANTIGENS, CD30; DIAGNOSIS, DIFFERENTIAL; HUMANS; IMMUNOHISTOCHEMISTRY; INTERFERON REGULATORY FACTORS; LYMPHOMA, LARGE-CELL, ANAPLASTIC; LYMPHOMATOID PAPULOSIS; LYMPHOPROLIFERATIVE DISORDERS; MULTIPLE MYELOMA; SKIN NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 43749098520     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/j.1365-2133.2008.08566.x     Document Type: Article

References (40)

1. Willemze R, Jaffe ES, Burg G et al. WHO-EORTC classification for cutaneous lymphomas. Blood 2005 105 : 3768 85.
2. Burg G, Jaffe ES, Kempf W et al. WHO/EORTC classification of cutaneous lymphomas. In : World Health Organization Classification of Tumours. Pathology and Genetics of Skin Tumours (LeBoit P, Burg G, Weedon D et al., eds). Lyon : WHO-IARC, 2006 166.
3. Kempf W, Willemze R, Jaffe ES et al. CD30+ T-cell lymphoproliferative disorders. In : World Health Organization Classification of Tumours. Pathology and Genetics of Skin Tumours (LeBoit P, Burg G, Weedon D et al., eds). Lyon : WHO-IARC, 2006 179 81.
4. Willemze R, Beljaards RC. Spectrum of primary cutaneous CD30 (Ki-1)-positive lymphoproliferative disorders. A proposal for classification and guidelines for management and treatment. J Am Acad Dermatol 1993 28 : 973 80.
5. Bekkenk MW, Geelen FA, van Voorst Vader PC et al. Primary and secondary cutaneous CD30(+) lymphoproliferative disorders: a report from the Dutch Cutaneous Lymphoma Group on the long-term follow-up data of 219 patients and guidelines for diagnosis and treatment. Blood 2000 95 : 3653 61.
6. Drews R, Samel A, Kadin ME. Lymphomatoid papulosis and anaplastic large cell lymphomas of the skin. Semin Cutan Med Surg 2000 19 : 109 17.
7. Kempf W. CD30+ lymphoproliferative disorders: histopathology, differential diagnosis, new variants, and simulators. J Cutan Pathol 2006 33 (Suppl. 1 58 70.
8. Droc C, Cualing HD, Kadin ME. Need for an improved molecular/genetic classification for CD30+ lymphomas involving the skin. Cancer Control 2007 14 : 124 32.
9. Grossman A, Mittrucker HW, Nicholl J et al. Cloning of human lymphocyte-specific interferon regulatory factor (hLSIRF/hIRF4) and mapping of the gene to 6p23-p25. Genomics 1996 37 : 229 33.
10. Iida S, Rao PH, Butler M et al. Deregulation of MUM1/IRF4 by chromosomal translocation in multiple myeloma. Nat Genet 1997 17 : 226 30.
11. Falini B, Fizzotti M, Pucciarini A et al. A monoclonal antibody (MUM1p) detects expression of the MUM1/IRF4 protein in a subset of germinal center B cells, plasma cells, and activated T cells. Blood 2000 95 : 2084 92.
12. Tsuboi K, Iida S, Inagaki H et al. MUM1/IRF4 expression as a frequent event in mature lymphoid malignancies. Leukemia 2000 14 : 449 56.
13. Natkunam Y, Warnke RA, Montgomery K et al. Analysis of MUM1/IRF4 protein expression using tissue microarrays and immunohistochemistry. Mod Pathol 2001 14 : 686 94.
14. Carbone A, Gloghini A, Aldinucci D et al. Expression pattern of MUM1/IRF4 in the spectrum of pathology of Hodgkin's disease. Br J Haematol 2002 117 : 366 72.
15. Valsami S, Pappa V, Rontogianni D et al. A clinicopathological study of B-cell differentiation markers and transcription factors in classical Hodgkin's lymphoma: a potential prognostic role of MUM1/IRF4. Haematologica 2007 92 : 1343 50.
16. Chang CC, Lorek J, Sabath DE et al. Expression of MUM1/IRF4 correlates with clinical outcome in patients with B-cell chronic lymphocytic leukemia. Blood 2002 100 : 4671 5.
17. Ito M, Iida S, Inagaki H et al. MUM1/IRF4 expression is an unfavorable prognostic factor in B-cell chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL). Jpn J Cancer Res 2002 93 : 685 94.
18. Sundram U, Kim Y, Mraz-Gernhard S et al. Expression of the bcl-6 and MUM1/IRF4 proteins correlate with overall and disease-specific survival in patients with primary cutaneous large B-cell lymphoma: a tissue microarray study. J Cutan Pathol 2005 32 : 227 34.
19. Muris JJ, Meijer CJ, Vos W et al. Immunohistochemical profiling based on Bcl-2, CD10 and MUM1 expression improves risk stratification in patients with primary nodal diffuse large B cell lymphoma. J Pathol 2006 208 : 714 23.
20. Heintel D, Zojer N, Schreder M et al. Expression of MUM1/IRF4 mRNA as a prognostic marker in patients with multiple myeloma. Leukemia 2008 22 : 441 5.
21. Kadin ME. Common activated helper-T-cell origin for lymphomatoid papulosis, mycosis fungoides, and some types of Hodgkin's disease. Lancet 1985 ii : 864 5.
22. Stein H, Foss HD, Durkop H et al. CD30(+) anaplastic large cell lymphoma: a review of its histopathologic, genetic, and clinical features. Blood 2000 96 : 3681 95.
23. Kadin ME, Carpenter C. Systemic and primary cutaneous anaplastic large cell lymphomas. Semin Hematol 2003 40 : 244 56.
24. Assaf C, Hirsch B, Wagner F et al. Differential expression of TRAF1 aids in the distinction of cutaneous CD30-positive lymphoproliferations. J Invest Dermatol 2007 127 : 1898 904.
25. Mao X, Orchard G, Russell-Jones R et al. Abnormal activator protein 1 transcription factor expression in CD30-positive cutaneous large-cell lymphomas. Br J Dermatol 2007 157 : 914 21.
26. DeCoteau JF, Butmarc JR, Kinney MC et al. The t(2;5) chromosomal translocation is not a common feature of primary cutaneous CD30+ lymphoproliferative disorders: comparison with anaplastic large-cell lymphoma of nodal origin. Blood 1996 87 : 3437 41.
27. Herbst H, Anagnostopoulos J, Heinze B et al. ALK gene products in anaplastic large cell lymphomas and Hodgkin's disease. Blood 1995 86 : 1694 700.
28. Bijl JJ, Rieger E, van Oostveen JW et al. HOXC4, HOXC5, and HOXC6 expression in primary cutaneous lymphoid lesions. High expression of HOXC5 in anaplastic large-cell lymphomas. Am J Pathol 1997 151 : 1067 74.
29. Sioutos N, Kerl H, Murphy SB et al. Primary cutaneous Hodgkin's disease. Unique clinical, morphologic, and immunophenotypic findings. Am J Dermatopathol 1994 16 : 2 8.
30. Cerroni L, Beham Schmid C, Kerl H. Cutaneous Hodgkin's disease: an immunohistochemical analysis. J Cutan Pathol 1995 22 : 229 35.
31. Herbst H, Sander C, Tronnier M et al. Absence of anaplastic lymphoma kinase (ALK) and Epstein-Barr virus gene products in primary cutaneous anaplastic large cell lymphoma and lymphomatoid papulosis. Br J Dermatol 1997 137 : 680 6.
32. Ponzoni M, Arrigoni G, Doglioni C. New transcription factors in diagnostic hematopathology. Adv Anat Pathol 2007 14 : 25 35.
33. Nguyen H, Hiscott J, Pitha PM. The growing family of interferon regulatory factors. Cytokine Growth Factor Rev 1997 8 : 293 312.
34. Matsuyama T, Grossman A, Mittrucker HW et al. Molecular cloning of LSIRF, a lymphoid-specific member of the interferon regulatory factor family that binds the interferon-stimulated response element (ISRE). Nucleic Acids Res 1995 23 : 2127 36.
35. Sundram U, Harvell JD, Rouse RV et al. Expression of the B-cell proliferation marker MUM1 by melanocytic lesions and comparison with S100, gp100 (HMB45), and MelanA. Mod Pathol 2003 16 : 802 10.
36. Mittrucker HW, Matsuyama T, Grossman A et al. Requirement for the transcription factor LSIRF/IRF4 for mature B and T lymphocyte function. Science 1997 275 : 540 3.
37. Yee AA, Yin P, Siderovski DP et al. Cooperative interaction between the DNA-binding domains of PU.1 and IRF4. J Mol Biol 1998 279 : 1075 83.
38. Uranishi M, Iida S, Sanda T et al. Multiple myeloma oncogene 1 (MUM1)/interferon regulatory factor 4 (IRF4) upregulates monokine induced by interferon-gamma (MIG) gene expression in B-cell malignancy. Leukemia 2005 19 : 1471 8.
39. Yamaguchi T, Ohshima K, Karube K et al. Expression of chemokines and chemokine receptors in cutaneous CD30+ lymphoproliferative disorders. Br J Dermatol 2006 154 : 904 9.
40. Beljaards RC, Kaudewitz P, Berti E et al. Primary cutaneous CD30-positive large cell lymphoma: definition of a new type of cutaneous lymphoma with a favorable prognosis. A European multicenter study of 47 patients. Cancer 1993 71 : 2097 104.